A detailed history of Sittner & Nelson, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sittner & Nelson, LLC holds 11,989 shares of BMY stock, worth $637,694. This represents 0.25% of its overall portfolio holdings.

Number of Shares
11,989
Previous 11,372 5.43%
Holding current value
$637,694
Previous $616,000 19.32%
% of portfolio
0.25%
Previous 0.32%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $24,834 - $32,694
617 Added 5.43%
11,989 $497,000
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $48,219 - $54,672
1,005 Added 9.69%
11,372 $616,000
Q4 2023

Feb 12, 2024

BUY
$48.48 - $57.85 $40,577 - $48,420
837 Added 8.78%
10,367 $531,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $3,183 - $3,560
-55 Reduced 0.57%
9,530 $553,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $1,274 - $1,414
20 Added 0.21%
9,585 $612,000
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $1,379 - $1,565
-21 Reduced 0.22%
9,565 $662,000
Q4 2022

Feb 01, 2023

BUY
$68.48 - $81.09 $205 - $243
3 Added 0.03%
9,586 $689,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $201 - $119,255
1,552 Added 19.33%
9,583 $681,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $84,529 - $93,096
1,164 Added 16.95%
8,031 $618,000
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $184 - $221
3 Added 0.04%
6,867 $502,000
Q4 2021

Feb 09, 2022

BUY
$53.63 - $62.52 $10,940 - $12,754
204 Added 3.06%
6,864 $428,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $177 - $207
3 Added 0.05%
6,660 $394,000
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $185 - $202
3 Added 0.05%
6,657 $445,000
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $3,501 - $3,937
59 Added 0.89%
6,654 $420,000
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $380,795 - $431,510
6,595 New
6,595 $409,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sittner & Nelson, LLC Portfolio

Follow Sittner & Nelson, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sittner & Nelson, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sittner & Nelson, LLC with notifications on news.